XML 30 R20.htm IDEA: XBRL DOCUMENT

Collaboration agreements (Tables)

9 Months Ended

Sep. 30, 2022

Schedule of Changes in the Balance of Our Contract Assets and Liabilities and Recognized Revenue

The following table presents changes in the balances of the Company's contract liabilities related to the GSK Agreement during the nine months ended September 30, 2022:


(in thousands)	Balance at Beginning of Period		Additions		Deductions		Balance at End of Period
Nine months ended September 30, 2022

Contract liabilities:
Deferred revenue	$	—	$	100,000	$	655	$	99,345

During the three and nine months ended September 30, 2022, the Company recognized the following revenues related to the GSK Agreement as a result of changes in the contract liability balances in the respective periods:


	Three Months Ended September 30,		Nine Months Ended September 30,
(in thousands)	2022		2022
Revenue recognized in the period from:
Amounts included in the contract liability at the beginning of the period	$	—	$	—
Performance obligations satisfied in previous periods	$	—	$	—

The following table presents changes in the balances of the Company's contract liabilities related to the Janssen Agreement during the nine months ended September 30, 2022:


(in thousands)	Balance at Beginning of Period		Additions		Deductions		Balance at End of Period
Nine months ended September 30, 2022

Contract liabilities:
Deferred revenue	$	—	$	40,000	$	10,916	$	29,084

During the three and nine months ended September 30, 2022, the Company recognized the following revenues related to the Janssen Agreement as a result of changes in the contract liability balances in the respective periods:


	Three Months Ended September 30,		Nine Months Ended September 30,
(in thousands)	2022		2022
Revenue recognized in the period from:
Amounts included in the contract liability at the beginning of the period	$	4,908	$	—
Performance obligations satisfied in previous periods	$	—	$	—

The following table presents changes in the balances of the Company's contract liabilities related to the Merck KGaA Agreement and Merck KGaA Supply Agreement during the nine months ended September 30, 2022 and 2021:


(in thousands)	Balance at Beginning of Period		Additions		Deductions		Balance at End of Period
Nine months ended September 30, 2022

Contract liabilities:
Deferred revenue	$	3,944	$	—	$	32	$	3,912


(in thousands)	Balance at Beginning of Period		Additions		Deductions		Balance at End of Period
Nine months ended September 30, 2021

Contract liabilities:
Deferred revenue	$	3,987	$	—	$	32	$	3,955

During the three and nine months ended September 30, 2022 and 2021, the Company recognized the following revenues related to the Merck KGaA Agreement and Merck KGaA Supply Agreement as a result of changes in the contract liability balances in the respective periods:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2022		2021		2022		2021
Revenue recognized in the period from:
Amounts included in the contract liability at the beginning of the period	$	11	$	11	$	32	$	32
Performance obligations satisfied in previous periods	$	—	$	—	$	—	$	—